{"id":36482,"date":"2018-05-29T15:40:00","date_gmt":"2018-05-29T13:40:00","guid":{"rendered":"https:\/\/www.ipsen.com\/press-releases\/ipsen-announces-clinical-data-to-be-presented-at-asco-demonstrating-its-commitment-to-patients-with-cancer\/"},"modified":"2024-07-29T08:04:46","modified_gmt":"2024-07-29T06:04:46","slug":"ipsen-announces-clinical-data-to-be-presented-at-asco-demonstrating-its-commitment-to-patients-with-cancer","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/press-releases\/ipsen-announces-clinical-data-to-be-presented-at-asco-demonstrating-its-commitment-to-patients-with-cancer\/","title":{"rendered":"Ipsen announces clinical data to be presented at ASCO demonstrating its commitment to patients with cancer"},"content":{"rendered":"<p><b>Paris (France), 29 May 2018<\/b>\u00a0\u2013 Ipsen (Euronext: IPN; ADR: IPSEY) today announced that<br \/>\ncabozantinib (Cabometyx\u00ae) and irinotecan liposome injection (Onivyde\u00ae) are the subject of 8<br \/>\npresentations at the 2018 American Society of Clinical Oncology (ASCO) annual meeting. The meeting takes place in Chicago, Illinois, June 1-5, 2018.<\/p>\n<p>Alexandre Lebeaut, Executive Vice President, R&amp;D and Chief Scientific Officer, Ipsen stated:<\/p>\n<blockquote><p>\u201cIpsen\u2019s oncology products, notably Onivyde\u00ae, Decapeptyl\u00ae and Cabometyx\u00ae, have been evaluated by many scientific teams around the world: either directly by investigators, our partners or by Ipsen. Results from some of these investigations will be the subject of oral abstract sessions. We are committed in our efforts against cancer, and through our interactions at ASCO 2018 we will continue to advance innovation for patient care in Oncology.\u201d<\/p><\/blockquote>\n<p><b>Cabozantinib (Cabometyx\u00ae) will be presented in 7 abstracts:<\/b><br \/>\n<b>Cabozantinib (Cabometyx\u00ae) will be featured in one oral poster discussion:<\/b><\/p>\n<ul>\n<li style=\"margin-bottom:3px\">[Abstract 4019] Poster 208 Discussion: Sunday, 3 June, 16:45\u201318:00, Hall D2<br \/>\no Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular<br \/>\ncarcinoma (HCC) who have received prior sorafenib: results from the randomized<br \/>\nphase 3 CELESTIAL trial<br \/>\no Presenting author: Ghassan Abou-Alfa [Sponsor: Exelixis]<\/li>\n<\/ul>\n<p><b>Cabozantinib (Cabometyx\u00ae) will be featured in other presentations:<\/b><\/p>\n<ul>\n<li style=\"margin-bottom:3px\">[Abstract 4556] Poster 382 \u2013 Category: Genitourinary (Nonprostate) Cancer; Saturday, 2 June, 8:00\u201311:30, Hall A<br \/>\no Title: Quality-adjusted time without symptoms or toxicity (Q-TWiST): Analysis of<br \/>\ncabozantinib (Cabo) vs sunitinib (Sun) in patients with advanced renal cell<br \/>\ncarcinoma (aRCC) of intermediate or poor risk (Alliance A031203)<br \/>\no Presenting author: Ronald Chen [Sponsor: Ipsen]<\/li>\n<li style=\"margin-bottom:3px\">[Abstract 4598] Poster 418a \u2013 Category: Genitourinary (Nonprostate) Cancer; Saturday, 2 June, 8:00\u201311:30, Hall A<br \/>\no A phase 3, randomized, open-label study of nivolumab combined with cabozantinib<br \/>\nvs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER)<br \/>\no Presenting author: Toni Choueiri [Sponsor: Bristol-Myers Squibb, Exelixis &amp; Ipsen]<\/li>\n<\/ul>\n<ul>\n<li style=\"margin-bottom:3px\">[Abstract 4601] Poster 419b \u2013 Category: Genitourinary (Nonprostate) Cancer; Saturday, 2 June, 8:00\u201311:30, Hall A<\/li>\n<li style=\"margin-bottom:3px\">o CANTATA: A randomized phase 2 study of CB-839 in combination with cabozantinib vs. placebo with cabozantinib in patients with advanced\/metastatic renal cell carcinoma<br \/>\no Presenting author: Nizar Tannir [Sponsor: Calithera Biosciences, Inc]<\/li>\n<\/ul>\n<ul>\n<li style=\"margin-bottom:3px\">[Abstract 4088] Poster 277 \u2013 Category: Gastrointestinal (Noncolorectal) Cancer; Sunday,<br \/>\n3 June, 8:00\u201311:30, Hall A<br \/>\no Outcomes based on receipt of sorafenib (S) as the only prior systemic therapy in the<br \/>\nphase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced<br \/>\nhepatocellular carcinoma (HCC)<br \/>\no Presenting author: Robin Kelley [Sponsor: Exelixis]<\/li>\n<\/ul>\n<ul>\n<li style=\"margin-bottom:3px\">[Abstract 4090] Poster 279 \u2013 Category: Gastrointestinal (Noncolorectal) Cancer; Sunday, 3<br \/>\nJune, 8:00\u201311:30, Hall A<br \/>\no Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus<br \/>\nplacebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC)<br \/>\no Presenting author: Lorenza Rimassa [Sponsor: Exelixis]<\/li>\n<\/ul>\n<ul>\n<li style=\"margin-bottom:3px\">[Abstract TPS 4157] Poster 333a \u2013 Category: Gastrointestinal (Noncolorectal) Cancer;<br \/>\nSunday, 3 June, 8:00\u201311:30, Hall A<br \/>\no A phase II trial of cabozantinib and erlotinib for patients with EGFR and c-MET coexpressing<br \/>\nmetastatic pancreatic adenocarcinoma<br \/>\no Presenting author: Olumide Gbolahan [Sponsor: Exelixis]<\/li>\n<\/ul>\n<p><b>nal-IRI \/ liposomal irinotecan (ONIVYDE\u00ae) will be featured in 1 poster:<\/b><\/p>\n<ul>\n<li style=\"margin-bottom:3px\">[Abstract 4111] Poster 300 \u2013 Category: Gastrointestinal (Noncolorectal) Cancer; Sunday, 3 June, 8:00\u201311:30, Hall A<br \/>\no A phase 1\/2, open-label dose-escalation study of liposomal irinotecan (nal-IRI) plus 5- fluorouracil\/leucovorin (5-FU\/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer (mPAC).<br \/>\no Presenting author: Andrew Dean [Sponsor: Ipsen]<\/li>\n<\/ul>\n<p><img src='https:\/\/ml-eu.globenewswire.com\/media\/OWYyNWJkODEtZDUwMC00NDUyLWI3NWYtZmZhNTBkZWEzZWI2LTEwMTA5NDM=\/tiny\/Ipsen-SA.png' \/><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[1763,1767,149],"tags":[],"class_list":["post-36482","press_release","type-press_release","status-publish","hentry","category-corporate-pressrelease","category-oncology-pressrelease","category-pressrelease","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ipsen announces clinical data to be presented at ASCO demonstrating its commitment to patients with cancer<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/press-releases\/ipsen-announces-clinical-data-to-be-presented-at-asco-demonstrating-its-commitment-to-patients-with-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen announces clinical data to be presented at ASCO demonstrating its commitment to patients with cancer\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/press-releases\/ipsen-announces-clinical-data-to-be-presented-at-asco-demonstrating-its-commitment-to-patients-with-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"article:modified_time\" content=\"2024-07-29T06:04:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml-eu.globenewswire.com\/media\/OWYyNWJkODEtZDUwMC00NDUyLWI3NWYtZmZhNTBkZWEzZWI2LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.ipsen.com\/press-releases\/ipsen-announces-clinical-data-to-be-presented-at-asco-demonstrating-its-commitment-to-patients-with-cancer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/press-releases\/ipsen-announces-clinical-data-to-be-presented-at-asco-demonstrating-its-commitment-to-patients-with-cancer\/\"},\"author\":{\"name\":\"IPSEN\",\"@id\":\"https:\/\/www.ipsen.com\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0\"},\"headline\":\"Ipsen announces clinical data to be presented at ASCO demonstrating its commitment to patients with cancer\",\"datePublished\":\"2018-05-29T13:40:00+00:00\",\"dateModified\":\"2024-07-29T06:04:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/press-releases\/ipsen-announces-clinical-data-to-be-presented-at-asco-demonstrating-its-commitment-to-patients-with-cancer\/\"},\"wordCount\":525,\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/press-releases\/ipsen-announces-clinical-data-to-be-presented-at-asco-demonstrating-its-commitment-to-patients-with-cancer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/OWYyNWJkODEtZDUwMC00NDUyLWI3NWYtZmZhNTBkZWEzZWI2LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"articleSection\":[\"Corporate\",\"Oncology\",\"Press Releases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/press-releases\/ipsen-announces-clinical-data-to-be-presented-at-asco-demonstrating-its-commitment-to-patients-with-cancer\/\",\"url\":\"https:\/\/www.ipsen.com\/press-releases\/ipsen-announces-clinical-data-to-be-presented-at-asco-demonstrating-its-commitment-to-patients-with-cancer\/\",\"name\":\"Ipsen announces clinical data to be presented at ASCO demonstrating its commitment to patients with cancer\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/press-releases\/ipsen-announces-clinical-data-to-be-presented-at-asco-demonstrating-its-commitment-to-patients-with-cancer\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/press-releases\/ipsen-announces-clinical-data-to-be-presented-at-asco-demonstrating-its-commitment-to-patients-with-cancer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/OWYyNWJkODEtZDUwMC00NDUyLWI3NWYtZmZhNTBkZWEzZWI2LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"datePublished\":\"2018-05-29T13:40:00+00:00\",\"dateModified\":\"2024-07-29T06:04:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/press-releases\/ipsen-announces-clinical-data-to-be-presented-at-asco-demonstrating-its-commitment-to-patients-with-cancer\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/press-releases\/ipsen-announces-clinical-data-to-be-presented-at-asco-demonstrating-its-commitment-to-patients-with-cancer\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ipsen.com\/press-releases\/ipsen-announces-clinical-data-to-be-presented-at-asco-demonstrating-its-commitment-to-patients-with-cancer\/#primaryimage\",\"url\":\"https:\/\/ml-eu.globenewswire.com\/media\/OWYyNWJkODEtZDUwMC00NDUyLWI3NWYtZmZhNTBkZWEzZWI2LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"contentUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/OWYyNWJkODEtZDUwMC00NDUyLWI3NWYtZmZhNTBkZWEzZWI2LTEwMTA5NDM=\/tiny\/Ipsen-SA.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/press-releases\/ipsen-announces-clinical-data-to-be-presented-at-asco-demonstrating-its-commitment-to-patients-with-cancer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen announces clinical data to be presented at ASCO demonstrating its commitment to patients with cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/#website\",\"url\":\"https:\/\/www.ipsen.com\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/www.ipsen.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ipsen.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ipsen.com\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0\",\"name\":\"IPSEN\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ipsen.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g\",\"caption\":\"IPSEN\"},\"sameAs\":[\"https:\/\/www.ipsen.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen announces clinical data to be presented at ASCO demonstrating its commitment to patients with cancer","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/press-releases\/ipsen-announces-clinical-data-to-be-presented-at-asco-demonstrating-its-commitment-to-patients-with-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Ipsen announces clinical data to be presented at ASCO demonstrating its commitment to patients with cancer","og_url":"https:\/\/www.ipsen.com\/press-releases\/ipsen-announces-clinical-data-to-be-presented-at-asco-demonstrating-its-commitment-to-patients-with-cancer\/","og_site_name":"Global","article_modified_time":"2024-07-29T06:04:46+00:00","og_image":[{"url":"https:\/\/ml-eu.globenewswire.com\/media\/OWYyNWJkODEtZDUwMC00NDUyLWI3NWYtZmZhNTBkZWEzZWI2LTEwMTA5NDM=\/tiny\/Ipsen-SA.png"}],"twitter_card":"summary_large_image","twitter_site":"@ipsengroup","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.ipsen.com\/press-releases\/ipsen-announces-clinical-data-to-be-presented-at-asco-demonstrating-its-commitment-to-patients-with-cancer\/#article","isPartOf":{"@id":"https:\/\/www.ipsen.com\/press-releases\/ipsen-announces-clinical-data-to-be-presented-at-asco-demonstrating-its-commitment-to-patients-with-cancer\/"},"author":{"name":"IPSEN","@id":"https:\/\/www.ipsen.com\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0"},"headline":"Ipsen announces clinical data to be presented at ASCO demonstrating its commitment to patients with cancer","datePublished":"2018-05-29T13:40:00+00:00","dateModified":"2024-07-29T06:04:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ipsen.com\/press-releases\/ipsen-announces-clinical-data-to-be-presented-at-asco-demonstrating-its-commitment-to-patients-with-cancer\/"},"wordCount":525,"publisher":{"@id":"https:\/\/www.ipsen.com\/#organization"},"image":{"@id":"https:\/\/www.ipsen.com\/press-releases\/ipsen-announces-clinical-data-to-be-presented-at-asco-demonstrating-its-commitment-to-patients-with-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/OWYyNWJkODEtZDUwMC00NDUyLWI3NWYtZmZhNTBkZWEzZWI2LTEwMTA5NDM=\/tiny\/Ipsen-SA.png","articleSection":["Corporate","Oncology","Press Releases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/press-releases\/ipsen-announces-clinical-data-to-be-presented-at-asco-demonstrating-its-commitment-to-patients-with-cancer\/","url":"https:\/\/www.ipsen.com\/press-releases\/ipsen-announces-clinical-data-to-be-presented-at-asco-demonstrating-its-commitment-to-patients-with-cancer\/","name":"Ipsen announces clinical data to be presented at ASCO demonstrating its commitment to patients with cancer","isPartOf":{"@id":"https:\/\/www.ipsen.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/press-releases\/ipsen-announces-clinical-data-to-be-presented-at-asco-demonstrating-its-commitment-to-patients-with-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/press-releases\/ipsen-announces-clinical-data-to-be-presented-at-asco-demonstrating-its-commitment-to-patients-with-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/OWYyNWJkODEtZDUwMC00NDUyLWI3NWYtZmZhNTBkZWEzZWI2LTEwMTA5NDM=\/tiny\/Ipsen-SA.png","datePublished":"2018-05-29T13:40:00+00:00","dateModified":"2024-07-29T06:04:46+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/press-releases\/ipsen-announces-clinical-data-to-be-presented-at-asco-demonstrating-its-commitment-to-patients-with-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/press-releases\/ipsen-announces-clinical-data-to-be-presented-at-asco-demonstrating-its-commitment-to-patients-with-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ipsen.com\/press-releases\/ipsen-announces-clinical-data-to-be-presented-at-asco-demonstrating-its-commitment-to-patients-with-cancer\/#primaryimage","url":"https:\/\/ml-eu.globenewswire.com\/media\/OWYyNWJkODEtZDUwMC00NDUyLWI3NWYtZmZhNTBkZWEzZWI2LTEwMTA5NDM=\/tiny\/Ipsen-SA.png","contentUrl":"https:\/\/ml-eu.globenewswire.com\/media\/OWYyNWJkODEtZDUwMC00NDUyLWI3NWYtZmZhNTBkZWEzZWI2LTEwMTA5NDM=\/tiny\/Ipsen-SA.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/press-releases\/ipsen-announces-clinical-data-to-be-presented-at-asco-demonstrating-its-commitment-to-patients-with-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/"},{"@type":"ListItem","position":2,"name":"Ipsen announces clinical data to be presented at ASCO demonstrating its commitment to patients with cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/#website","url":"https:\/\/www.ipsen.com\/","name":"Global","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/#organization","name":"IPSEN","url":"https:\/\/www.ipsen.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ipsen.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/www.ipsen.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]},{"@type":"Person","@id":"https:\/\/www.ipsen.com\/#\/schema\/person\/81bf851fdec8a6fd535e94f631c502b0","name":"IPSEN","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ipsen.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9567f50289ed3f8d4c65927e8de9f6fc?s=96&d=mm&r=g","caption":"IPSEN"},"sameAs":["https:\/\/www.ipsen.com"]}]}},"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/press_release\/36482"}],"collection":[{"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":1,"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/press_release\/36482\/revisions"}],"predecessor-version":[{"id":36487,"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/press_release\/36482\/revisions\/36487"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/media?parent=36482"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/categories?post=36482"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/tags?post=36482"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}